Apyx Medical (APYX) vs Pulmonx (LUNG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pulmonx (LUNG) has outperformed Apyx Medical (APYX) over the past year, gaining 78.5% versus a loss of 40.0%. Over five years, APYX leads with a -83.4% price change compared with -92.4% for LUNG. Pulmonx is the larger company by market cap ($111.9 million vs $101.1 million), about 1.1 times the size, while Apyx Medical is growing revenue faster (+9.9% vs +8.0%).
Apyx Medical converts more of its revenue into profit, with a net margin of -21.2% versus -59.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APYX | LUNG |
|---|---|---|
| Share price | $2.40 | $2.57 |
| Market cap | $101.10M | $111.93M |
| 1-day change | +0.42% | -6.20% |
| YTD return | -31.43% | +16.29% |
| 1-year return | -40.00% | +78.47% |
| 5-year return | -83.40% | -92.39% |
| EPS (TTM) | $-0.19 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $52.84M | $90.50M |
| Revenue growth (YoY) | +9.86% | +8.01% |
| Net income (latest FY) | $-11.21M | $-54.00M |
| Gross margin | 62.53% | 74.19% |
| Operating margin | -12.20% | -59.30% |
| Net margin | -21.22% | -59.67% |
| 52-week high | $5.08 | $3.25 |
| 52-week low | $2.25 | $1.13 |
| Distance from 52-week high | -52.76% | -20.92% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +170.83% | +65.37% |
| Average volume | 146.81K | 641.52K |
| Shares outstanding | 42.12M | 43.55M |
| Employees | 205 | 296 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LUNG has outperformed APYX by 118.5 percentage points over the past year.
- Apyx Medical is more profitable, keeping -21.2 cents of every revenue dollar as net income versus -59.7 cents for Pulmonx.
About Apyx Medical
APYX stock →Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM).
Health Care · Medical/Dental Instruments · 205 employees
About Pulmonx
LUNG stock →Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Health Care · Medical/Dental Instruments · 296 employees
APYX vs LUNG FAQ
Which is bigger, Apyx Medical or Pulmonx?
Pulmonx (LUNG) is larger, with a market capitalization of $111.93M compared with $101.10M for Apyx Medical (APYX).
Which stock has performed better over the past year, APYX or LUNG?
LUNG returned +78.47% over the past 12 months, compared with -40.00% for APYX (price return, excluding dividends). Past performance does not predict future results.
Are Apyx Medical and Pulmonx in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.